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Abstract The role of Grb7 adapters, Grb7, Grb10, and Grb14,
was investigated in Xenopus oocytes expressing ¢broblast
growth factor receptors (FGFR). FGF-induced maturation of
FGFR-expressing oocytes was blocked by previous injection of
Grb7 or Grb14, but not Grb10. This e¡ect correlated with
Grb7/14 binding to the receptor, and inhibition of the Ras-de-
pendent pathway. Interestingly, the phosphorylated insulin re-
ceptor interacting region (PIR) and Src 2 homology domains
(SH2) of Grb7 and Grb14 were di¡erently implicated in the
inhibition of FGFR signalling. This study provided further evi-
dence for speci¢city of the biological action of the Grb7 adapt-
ers on receptor tyrosine kinase signalling.
/ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
Key words: Fibroblast growth factor receptor; Grb7 family;
ERK2; PI3-kinase; Xenopus oocyte; MDA-MB-231 cell line
1. Introduction
Fibroblast growth factor receptors (FGFRs) are involved in
the regulation of a wide variety of cellular processes [1]. Four
FGFR genes have been cloned to date, each coding for a
transmembrane protein with a cytoplasmic tyrosine kinase
domain. As for many growth factor receptors, binding of an
appropriate ligand results in receptor dimerisation, which
leads to the activation of the cytoplasmic tyrosine kinase do-
main [2]. Following these events, intracellular proteins are
recruited by the receptor and a complex network of transduc-
tion cascades is elicited. The multiprotein complexes docked
by the receptor include adapter proteins such as Shc, FGFR-
substrate 2 (FRS2) and Grb2, and enzymes, such as phospha-
tidylinositol-3 kinase (PI3-kinase), phospholipase C gamma
(PLCQ) [3^6].
The growth factor receptor-bound protein 7 (Grb7) family
of adapters comprises three members, Grb7, Grb10 and
Grb14, which interact with numerous receptor tyrosine ki-
nases upon activation [7], including insulin-like growth fac-
tor-1 receptor (IGF-1R), insulin receptor (IR) [8^10], plate-
let-derived growth factor receptor (PDGFR) [11], epidermal
growth factor receptor (EGFR) [12] and the Ret proto-onco-
gene [13]. Grb10 [14] and Grb14 [15] have also been shown to
bind to FGFR in cell lines. Members of the Grb7 family of
adapters interact with the activated tyrosine kinase domain of
the receptors using their C terminal region which contains two
binding domains, the PIR/BPS (for phosphorylated IR inter-
acting region/between plextrin-homology and Src homology 2
(SH2)), and the SH2 domain. Participation of these two do-
mains in receptor binding di¡ers considering the various part-
ners. The SH2 domain is involved in most interactions with
receptor tyrosine kinases, at the exception of the IR-Grb14
binding [10,14^16]. In contrast, the PIR is likely to be impli-
cated in the association between the members of the Grb7
family of proteins and the related receptors IR and IGF-1R
[10,16^20]. A critical role for the PIR in the interaction with
other receptors has not yet been reported.
The function of the Grb7 family members is not fully
understood. Despite controversial ¢ndings, each member is
likely to act as a negative regulator in several physiological
processes, and is deregulated in cancers. Grb7 may have a role
in kidney development [21], in breast and oesophageal carci-
noma progression [22^25]. In addition, an overexpression is
noticed for Grb7 in numerous breast tumours [25], and for
Grb10 and Grb14 in several breast and prostate cancer cell
lines [26,27]. Despite contradictory results obtained on Grb10
isoforms [14,28,29], their overexpression is consistent with an
inhibitory role in insulin signalling [17,30,31]. Moreover,
growing evidences are also emerging for an inhibitory role
of Grb14 in insulin signalling: Grb14 inhibits IR catalytic
activity, phosphorylation of its downstream targets IRS-1,
Akt and ERK1/2, and insulin stimulation of DNA and gly-
cogen synthesis [18,19].
To better understand the role played by the Grb7 family of
adapters in FGFR signalling, we have used a model system
devoid of FGFRs, the Xenopus oocyte, where FGFRs can be
expressed and stimulated by exogenous FGFs [32^34]. Xeno-
pus oocyte o¡ers a variety of powerful experimental ap-
proaches to question cascade transduction regulation. They
are physiologically arrested at the G2 stage of the ¢rst meiosis
prophase. Progesterone [35] and growth factors such as insu-
lin [36,37] or FGF [5,32^34], when binding to appropriate
receptors, induce the entry of oocytes into the M phase, which
leads to a germinal vesicle breakdown (GVBD), used as an
indicator of the meiosis reinitiation (maturation). The trans-
duction cascades involved in meiosis reinitiation include a
PKA-dependent pathway after progesterone stimulation, and
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Ras-dependent and -independent pathways after growth fac-
tor addition [5,38]. The mitogen-activated protein (MAP) ki-
nase cascade is activated in a all-or-none fashion, which al-
lows a very sensitive detection of oocyte signalling pathways
activation [39]. In the present study, we have analysed the
e¡ects of Grb7, Grb10, and Grb14 on FGF1-induced oocyte
maturation in oocytes expressing di¡erent FGFRs: FGFR1
or FGFR4 isoforms, and mRNAs from the breast cancer cell
line MDA-MB-231 [40], which mainly expresses FGFR1 and
FGFR4 [41]. Furthermore, we have analysed the involvement
of the PIR and the SH2 domains on oocyte maturation. These
results were further compared to the e¡ect of Grb7 proteins
on insulin-induced oocyte maturation, since Xenopus oocytes
naturally possess receptors for insulin [38].
2. Materials and methods
2.1. Oocyte handling
After anaesthesia with MS 222 (1 g/l, Sandoz, Vienna, Austria),
Xenopus laevis ovarian fragments were surgically removed and placed
in ND96 medium (in mM: NaCl 96, KCl 2, MgCl2 1, CaCl2 1.8,
HEPES 5, adjusted to pH 7.4 with NaOH), supplemented with strep-
tomycin/penicillin (50 Wg/ml, Eurobio, Les Ullys, France), sodium py-
ruvate (225 Wg/ml, Sigma, Saint Quentin Fallavier, France) and soy-
bean trypsin inhibitor (30 Wg/ml, Sigma) [5,32^34]. Stage VI oocytes
were harvested by using 1 h treatment with collagenase A (1 mg/ml,
Roche Boehringer, Meylan, France). Complete defolliculation of the
oocytes was achieved by manual dissection. The oocytes were kept at
19‡C in the ND96 medium.
2.2. RNA and fusion protein preparation
FGFR1 and FGFR4 from Pleurodeles waltlii, highly homologous
to the human receptors [42], and the chimera composed of the human
extracellular domain of the PDGF receptor and the intracellular do-
main of P. waltlii FGFR1 (gift from Dr D.L. Shi) inserted into vector
pSP64T [42] were used to generate capped cRNAs (mMESSAGE
mMACHINE kit, Ambion Austin, USA). PolyA mRNAs from
MDA-MB-231 breast cancer cell line were extracted by the guanidium
thiocyanate/cesium chloride gradient, using RNA plus reagent from
Bioprobe followed by polydT columns (Pharmacia Biotech, Orsay,
France) [40]. Grb7 adapter members, PIR, SH2, and PIR^SH2 do-
mains were produced as glutathione S-transferase (GST) fusions as
described before [10,18,19].
2.3. Microinjections, and GVBD analysis
All microinjections were performed in the equatorial region of the
oocyte. Microinjection of 60 ng of FGFR mRNAs was performed 48 h
before the injection of the Grb7 family members, Grb7, Grb10, or
Grb14, or of their PIR, SH2, or PIR^SH2 domains. One hour after
the injection of the fusion proteins, oocytes were stimulated with 5 nM
FGF1. GVBD was determined by the appearance of a white spot at
the centre of the animal pole, 15 h after the FGF1 treatment. Stu-
dent’s t-test was used to assess the signi¢cance of the observed di¡er-
ences. For each experiments, 20^30 oocytes were removed from at
least two animals.
2.4. Immunoprecipitation of the PDGFR^FGFR1 chimera
20 oocytes expressing for 48 h the PDGFR^FGFR1 chimera were
injected with Grb7, Grb10 or Grb14 (100 ng), 1 h before stimulation
by PDGF-BB (5 nM). After 5 min, these oocytes were lysed in 200 Wl
of bu¡er A: 50 mM HEPES, pH 7.4, 1% Triton X-100, 500 mM
NaCl, 0.05% SDS, 5 mM MgCl2, 1 mg/ml bovine serum albumin,
10 Wg/ml leupeptin, 10 Wg/ml aprotinin, 10 Wg/ml soybean trypsin
inhibitor, 10 Wg/ml benzamidine, 1 mM PMSF, 1 mM sodium vana-
date. A centrifugation of 10 000Ug for 15 min at 4‡C was then per-
formed. Supernatants were incubated with anti-PDGFR antibodies
(that react with the extracellular domain of the chimera, RpD system,
Abington, UK), for 2 h at 4‡C. Protein A-Sepharose (50%, BD Bio-
sciences, Erembodegem, Belgium) was added for 1 h at 4‡C. Immuno-
complexes were collected by centrifugation, rinsed three times, resus-
pended in Laemmli sample bu¡er, and subjected to a 7.5% SDS^
PAGE.
2.5. Electrophoresis and western blot analysis
For western blot analysis, oocytes were homogenised in ice cold
bu¡er A as previously described and electrophoresis was performed
[5]. Proteins were transferred to a Hybond ECL membrane (Amer-
sham Biosciences, Freiburg, Germany) in Tris/NaCl/Tween/BSA pH8
(15 mM Tris-HCl, 150 mM NaCl, 0.1% Tween, 10% bovine serum
albumin, Sigma).
To analyse the association of Grb7 members with receptors in the
immunoprecipitation experiments, the membranes were ¢rst immu-
norevealed with anti-phosphotyrosine antibodies (BD Biosciences).
The membranes were then stripped and reprobed with anti-PDGFR
antibodies (BD Biosciences). The lower part of the membrane were
cut and blotted with anti-Grb7 antibodies (BD Transduction Labo-
ratories) for the oocyte samples injected with Grb7, with anti-Grb10
antibodies (BD Biosciences) for the oocyte samples injected with
Grb10 or with anti-Grb14 antibodies [18] for the oocyte samples in-
jected with Grb14.
For transduction analysis, samples were prepared as described
[33,34], and electrophoresis was performed on 15% modi¢ed polyac-
rylamide gels (30% acrylamide, and 0.2% bisacrylamide). The mem-
branes were incubated either with anti-ERK2 (Santa Cruz Biotechnol-
ogy, Santa Cruz, USA), with anti-Raf (Santa Cruz Biotechnology),
with anti-phosphorylated Akt (BD Biosciences), or with anti-L-catenin
(BD Biosciences) antibodies. Antibodies complexes were detected by
the enhanced chemiluminescence western blotting detection system
(Amersham).
3. Results
3.1. E¡ects of Grb7 family members on FGFR-induced oocyte
maturation
Oocytes were injected with FGFR1 or FGFR4 cRNA, or
MDA-MB-231 polyA mRNA. After 48 h of expression, the
addition of 5 nM FGF1 triggered meiosis reinitiation, moni-
tored by GVBD observation (Fig. 1). GVBD appearance
takes an average of 15 h after FGF1 addition, as previously
described [5,40]. When injected with 100 ng of Grb7 or Grb14
1 h before the addition of FGF1, oocytes expressing FGFRs
did not present any GVBD (Fig. 1), even 48 h after FGF1
stimulation (data not shown). In contrast, Grb10 did not
block oocyte maturation. Control oocytes injected with GST
Fig. 1. E¡ect of Grb7, Grb10 and Grb14 on FGF- and insulin-in-
duced oocyte maturation. Oocytes expressing FGFR1 (R1), FGFR4
(R4) or FGFRs from MDA-MB-231 cell line (Rs) for 48 h were in-
jected with 100 ng of Grb7, or Grb10, or Grb14, or GST and
treated with 5 nM FGF1. Naive oocytes (IR) that naturally possess
IRs were injected with 100 ng of Grb7, or Grb10, or Grb14, or
GST and stimulated with 1 WM insulin. Controls (0) were realised
without the injection of Grb fusion proteins. Oocyte maturation
was assessed by GVBD detection. Results are expressed as percent-
age of GVBD observed on the oocytes, and are the meanSS.E.M.
of three to 11 independent experiments.
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alone (100 ng) displayed FGF1-induced maturation (Fig. 1),
and Grb7 adapters had no e¡ect on naive oocytes or on oo-
cytes expressing FGFRs when let unstimulated. In naive oo-
cytes, that naturally express the IR, stimulation with 1 WM
insulin induced oocyte maturation, as previously described
[43]. Injections of either Grb7, Grb10 or Grb14 blocked
GVBD appearance (Fig. 1, right part).
3.2. Role of PIR and SH2 domains of Grb7 members
The PIR and PIR^SH2 domains of Grb7 injected in oocytes
expressing FGFRs totally blocked FGF1-induced maturation,
whereas the SH2 domain alone was ine⁄cient to inhibit it
(Fig. 2A). Control experiments using naive oocytes demon-
strated that the PIR, the SH2 or the PIR^SH2 domains of
Grb7 blocked insulin-induced GVBD. For Grb10, none of
these domains had any e¡ect on FGF1-induced GVBD, but
all domains blocked insulin-induced oocyte maturation (Fig.
2B). Concerning Grb14, the PIR and the SH2 domains as well
as the PIR^SH2 domain totally suppressed FGF1-induced
GVBD. In contrast, only the PIR or the PIR^SH2 domains
of Grb14, but not the SH2 domain, inhibited insulin-induced
oocyte maturation (Fig. 2C).
We performed dose^response experiments to test the sensi-
tivity of the inhibition of oocyte maturation by the di¡erent
Grb fusion proteins. However, oocyte maturation is an all or
none type of response [39]. A given amount of injected protein
is or not su⁄cient to block GVBD, in a similar way in all
oocytes tested, avoiding a classical dose^response curve. Thus,
as shown in Fig. 3, microinjection of 50 ng of Grb7 or Grb14
did not a¡ect FGF1 induced oocyte maturation, whereas 75
ng blocked FGF1 e¡ect in 100% of the oocytes. By compar-
ison, microinjection of 50 ng of PIR, SH2 or PIR^SH2 do-
mains Grb7 or Grb14 were su⁄cient to block FGF1-induced
oocyte maturation. When these results are expressed in pmol
of proteins injected in each oocyte, it appears that 0.85 pmol
of Grb7 or Grb14 were inhibitory, but about 1.4 pmol of the
isolated domains PIR or SH2 were needed for a similar e¡ect.
Fig. 2. E¡ect of the PIR and SH2 domains of Grb7, Grb10 and
Grb14 on FGF- and insulin-induced oocyte maturation. Percentage
of GVBD observed on naive oocytes (IR) stimulated with insulin
and on oocytes expressing FGFR1 (R1), FGFR4 (R4), or FGFRs
from MDA-MB-231 cell line (Rs) treated with FGF1 and injected
with full length, PIR, SH2, or PIR^SH2 domain of Grb7 (A),
Grb10 (B), or Grb14 (C). Controls were realised without injection
of the fusion proteins (0). Results are expressed as percentage of
GVBD observed on the oocytes, and are the meanSS.E.M. of two
to 11 independent experiments.
Fig. 3. Dose-response e¡ect of PIR, SH2, PIR^SH2 domains and
full length Grb7 (A) and Grb14 (B) on oocyte expressing FGFR1
and stimulated by FGF1. Percentage of GVBD observed are the
meanSS.E.M. of two to three independent experiments.
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Interestingly, 0.87 pmol (40 ng) of the Grb14 PIR^SH2 ap-
peared to represent the lower amount of protein able to in-
hibit FGF-induced oocyte maturation, showing that this re-
gion is as e¡ective as the full length protein. In contrast, 1.1
pmol (50 ng) of Grb7 PIR^SH2 are required to block GVBD.
3.3. Association of FGFR1 with the members of
the Grb7 family
We then tested whether the inhibitory e¡ect of Grb7 and
Grb14 on FGF1-induced oocyte maturation depended on an
association with FGFRs. We used the PDGFR^FGFR1 chi-
mera since available antibodies directed against FGFR did
not cross react with FGFR1 from Pleurodeles. This chimeric
receptor is e⁄ciently precipitated by anti-PDGFR antibodies
[34]. Furthermore, PDGF-BB induced maturation of oocytes
expressing this chimera [5]. Naive oocytes and oocytes ex-
pressing the PDGFR^FGFR1 chimera for 48 h, were injected
with either Grb7, Grb10 or Grb14 (100 ng). One hour after
these injections, oocytes were stimulated or not by PDGF-BB
for 5 min, and oocyte lysates were immunoprecipitated using
anti-PDGFR antibodies. As shown in Fig. 4, PDGF-BB in-
duced tyrosine phosphorylation of the chimeric receptor
(upper blots). In addition, ligand stimulation induced interac-
tion between the phosphorylated receptor and Grb7 or Grb14,
whereas no interaction could be detected with Grb10 (middle
blots). We veri¢ed that receptors were expressed at similar
levels in oocytes injected with the di¡erent Grb proteins (low-
er blots). Control experiments performed on naive oocytes
stimulated with PDGF-BB, showed that immunoprecipitation
of Grb7 and Grb14 with anti-PDGFR antibodies was depen-
dent on PDGFR expression (Fig. 4, lanes 1, 4 and 7). These
results provided evidence that the inhibitory e¡ect of Grb7
and Grb14 on FGF-induced oocyte maturation correlated
with their ability to bind to activated FGFR1.
3.4. Grb7 and Grb14 act on two main FGFR1 signalling
cascade
FGF-induced oocyte maturation is associated with the ac-
tivation of the MAP kinase pathway, characterised by the
phosphorylation of Raf and ERK2, the activation of the
PI3-kinase pathway seen by the phosphorylation of Akt,
and the accumulation of L-catenin (Fig. 5, lane 1). We thus
tested whether Grb7 and Grb14 injection altered these path-
ways in FGFR-expressing oocytes. As reported in Fig. 5, the
injection of Grb7 or Grb14 suppressed Raf, ERK2 and Akt
phosphorylation, and enhanced L-catenin degradation in
FGF1 stimulated oocytes expressing FGFR1 (Fig. 5, lanes 3
and 7). As expected, the injection of Grb10 had no e¡ect
(Fig. 5, lane 5). Control experiments performed on oocytes
let unstimulated, displayed no Raf, ERK2 or Akt phos-
phorylation, and only a low level of L-catenin (Fig. 5, lanes
2, 4, 6).
4. Discussion
The role of Grb7 family members was assessed using an
integrated biological system, the Xenopus oocyte, which is
devoid of endogenous FGFRs. In this system a speci¢c ex-
pression of FGFRs is obtained after injection of FGFR1,
FGFR4 or FGFRs from a highly invasive hormono-indepen-
dent breast cancer cell line, MDA-MB-231. Xenopus oocytes
react as an all or none system after FGFR activation, through
a Ras/MAP kinase cascade that lead the oocyte to enter into
the M phase of the cell cycle [39]. This allowed us to analyse
in a single experimental model the e¡ect of the Grb7 family
members on transduction cascades activated by FGFRs. In
addition, a comparison of these results with other RTKs ex-
pressed in the oocyte, the endogenous IR and IGF-1R, was
achieved.
The present study provided evidence that members of Grb7
family adapters can interfere with FGFR signalling, with a
given speci¢city for each protein. Grb7 and Grb14 inhibited
FGF-induced oocyte maturation, whereas Grb10 had no ef-
fect. Similar results were obtained for FGFR1, FGFR4, and
FGFRs from MDA-MB-231. This study reports the role of all
members of the Grb7 family in FGF signal transduction, and
is in agreement with a previous work reporting an inhibition
of FGF-stimulated DNA synthesis in a stable cell line over-
Fig. 4. Binding of Grb7, Grb10 and Grb14 to FGFR. Oocytes ex-
pressing a PDGFR^FGFR1 chimera for 48 h were injected with
Grb7, Grb10 or Grb14 and treated or not with 5 nM PDGF-BB.
After 5 min of stimulation, oocytes were lysed, immunoprecipitated
with anti-PDGFR antibodies, and immunoblotted with anti-phos-
photyrosine antibodies (anti-pTyr). The membrane was then
stripped and immunoblotted with anti-PDGFR antibodies. Lower
part of the membrane were further immunodetected with anti-Grb7,
anti-Grb10 or anti-Grb14 antibodies.
Fig. 5. E¡ect of Grb7, Grb10 and Grb14 on intracellular signalling.
FGFR1-expressing oocytes were injected with Grb7, Grb10 or
Grb14 and treated or not with 5 nM FGF1. After 15 h, oocytes
were processed as described and lysates were submitted to western
blot analysis. Immunodetections were performed with anti-Raf, anti-
ERK2 antibodies (the phosphorylated state of Raf and ERK2 is
shown by the upper arrow), anti-phosphorylated Akt, Ser 473 (anti-
pAkt,) and anti-L-catenin (anti-L cat) antibodies, as indicated.
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expressing Grb14 [15]. Inhibition of insulin signalling by
Grb14 was already established, in cell lines and in Xenopus
oocytes [18,43], but the present work gives also the ¢rst evi-
dence of an inhibition of insulin signalling by Grb7. Injection
of increasing amounts of fusion proteins showed that, for
both Grb7 and Grb14, 40 ng were needed to observe an in-
hibitory action. In contrast, 50 ng of Grb14 were su⁄cient to
inhibit insulin-induced oocyte maturation, whereas 100 ng of
Grb7 or Grb10 were required for the same e¡ect (data not
shown). These results suggest that FGFR signalling exhibits
similar sensitivity towards Grb7 and Grb14 but is insensitive
to Grb10, whereas IR signalling is sensitive to Grb7, Grb10,
and Grb14 inhibitory action.
The inhibitory e¡ect of the Grb proteins on FGF-induced
oocyte maturation nicely correlates with their binding ability
to the receptors in this biological system. An interaction be-
tween Grb7 and FGFR was already reported in the two-hy-
brid system [10], and Grb14 was also shown to bind to
FGFR1 in the two-hybrid system and in vitro binding assays
[15]. Grb10 did not bind to phosphorylated FGFR1 after li-
gand stimulation of receptor expressing oocytes, and was also
unable to alter oocyte GVBD. This is in contrast with a pre-
vious study reporting an in vitro interaction between the SH2
domain of Grb10 expressed in fusion with GST and activated
FGFR1 [14]. However, huge amount of proteins can be used
in GST pull-down experiments, allowing the detection of
weak interactions. In contrast, in the present work, similar
amounts of receptors were expressed in presence of the same
amount of injected Grb proteins. In such conditions, Grb7
and Grb14, but not Grb10, bound to activated FGFR, and
inhibited oocyte maturation. All together, these results suggest
that Grb10 is unlikely to play a physiological role in FGFR
signalling.
Inhibition of FGF induced oocyte maturation by Grb7 and
Grb14 was reproduced by their C-terminal region, containing
the PIR and SH2 domains. Interestingly, testing separately
these two domains, gave evidence that Grb7 and Grb14
seemed to interfere with FGFR signalling through speci¢c
mechanisms. The inhibitory action of Grb7 was only due to
the PIR, whereas both PIR and SH2 of Grb14 were able to
block GVBD induced by FGF^FGFR signalling. By compar-
ison, the PIR and SH2 domains of Grb7 and Grb14 exhibited
also di¡erent inhibitory e¡ects on insulin-induced reinitiation
of meiosis : both PIR and SH2 domains of Grb7 could block
insulin-induced oocyte maturation, but only the PIR of Grb14
was e⁄cient, as previously reported [43]. Thus, the isolated
domains of Grb7 and Grb14 able to inhibit insulin signalling
in Xenopus oocyte are those responsible for the interaction
with the IR [10,18]. However, such a correlation is not so
clear for FGFR. Grb14 binding to activated FGFR1 is
mainly mediated by the SH2 domain, and no participation
of the PIR was reported [15]. Furthermore, two-hybrid experi-
ments suggested that the SH2, but not the PIR, was impli-
cated in the FGFR1-Grb7 interaction (V.B. and A.F.B., un-
published data). This suggests that, besides a direct interaction
between the two proteins, other mechanisms should also be
important for the inhibition of FGFR signal transduction by
the members of the Grb7 family of adapters. A number of
hypothesis can be proposed to explain this e¡ect. First, mem-
bers of the Grb7 family of adapters can act as direct inhibitors
of receptor tyrosine kinase activity, as demonstrated for the
IR [17,19]. Furthermore, this inhibitory e¡ect is dependent on
the PIR domain [17,19]. PIR domains of both Grb7 and
Grb14 blocked reinitiation of meiosis in FGF stimulated oo-
cytes. However, as discussed above, they do not appear to
bind to FGFR, implying that their action is not linked to a
direct inhibition of the receptor catalytic activity. On the other
hand, the SH2 domain of Grb14 interacts with the phosphor-
ylated tyrosyl residues Y766 and Y776 in the C-terminus of
FGFR1 [15]. Y766 is phosphorylated after ligand addition,
and is the binding site for PLCQ [4]. We have previously re-
ported that FGF1-induced GVBD in FGFR1-expressing oo-
cyte is dependent on PLCQ, and that the inhibition of PLCQ
blocked ERK2 phosphorylation [5]. Thus, a competition be-
tween PLCQ and Grb14 on this binding site could inhibit
GVBD through an inhibition of the Ras/Raf/ERK2 pathway.
A report mention that FGFR1 mediated activation of PI3-
kinase was dependent on the same Y766 site, in aortic endo-
thelial cells under FGF2 stimulation [44]. We have previously
reported that FGF1-induced GVBD in FGFR1-expressing
oocyte is dependent on PI3-kinase, and that the inhibition
of PI3-kinase blocked ERK2 phosphorylation [5]. Finally, ex-
pression of a Grb14 SH2-mutant unable to bind to FGFR,
potentiated FGF-induced cellular proliferation. This suggests
that Grb14 e¡ect is mediated by its interaction with unidenti-
¢ed downstream e¡ectors [15]. Nevertheless, further studies
are needed to elucidate the molecular mechanisms of Grb7
and Grb14 inhibition of FGFR signalling.
FGF1 stimulation of oocytes expressing FGFR1, FGFR4
or FGFRs from MDA-MB-231 cells triggers Ras-dependent
and Ras-independent transduction cascades [40]. In Xenopus
oocytes, ERK2 is the main activated MAP kinase [45], Raf is
phosphorylated [46], and Akt is phosphorylated and activated
as a downstream target of PI3-kinase [5,47]. Injection of Grb7
or Grb14 induced a decrease in phosphorylation of Raf,
ERK2 and Akt, showing that two main transduction cascades
activated by FGFR1, the Raf-ERK2 and the PI3-kinase cas-
cades, were inhibited. The PI3-kinase pathway also leads to
inactivation of GSK-3, and to the accumulation of L-catenin.
We showed that L-catenin was no longer expressed in FGFR-
expressing oocytes injected with Grb7 or Grb14 before FGF1
stimulation. This suggests that injection of Grb7 or Grb14
released the inhibitory e¡ect of GSK-3 and allowed L-catenin
degradation, thus con¢rming that the upstream PI3-kinase
was no longer activated. We veri¢ed that injection of Grb7
or Grb14 did not alter oocyte maturation induced by proges-
terone, the natural inducer (data not shown). In progesterone-
stimulated oocytes, PI3-kinase blocked GSK-3 and L-catenin
was not degraded [45,48]. Furthermore, we previously re-
ported that PI3-kinase sets upstream from Ras in the trans-
duction pathways activated by FGF1^FGFR1 [5]. Conse-
quently, the action of Grb7 and Grb14 in FGFR signalling
is directed towards the Ras-dependent cascade, upstream from
Raf, presumably on molecular e¡ectors such as PLCQ or PI3-
kinase.
In conclusion, the Xenopus oocyte model provided a useful
system to delineate the role of the members of the Grb7 fam-
ily of adapters on signalling induced by various tyrosine ki-
nase receptors. Using this integrated biological model, we
showed that Grb7, Grb10 and Grb14 and their PIR and or
SH2 domain di¡erently interfered with FGFR and IR signal-
ling. Furthermore, we also provided evidence that the Grb
proteins inhibit upstream e¡ectors of the Ras pathway in
FGFR signalling.
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